Intellia Therapeutics, Inc. (NTLA) Reaches $25.13 After 8.00% Up Move; ACTUA (ACTA) Shorts Raised By 0.04%

June 12, 2018 - By Henry Gaston

Actua Corporation (NASDAQ:ACTA) Logo

ACTUA CORP (NASDAQ:ACTA) had an increase of 0.04% in short interest. ACTA’s SI was 233,500 shares in June as released by FINRA. Its up 0.04% from 233,400 shares previously. With 423,700 avg volume, 1 days are for ACTUA CORP (NASDAQ:ACTA)’s short sellers to cover ACTA’s short positions. The SI to ACTUA CORP’s float is 0.89%. The stock decreased 4.76% or $0.05 during the last trading session, reaching $1. About shares traded. Actua Corporation (NASDAQ:ACTA) has 0.00% since June 12, 2017 and is . It has underperformed by 12.57% the S&P500.

The stock of Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a huge mover today! The stock increased 2.32% or $0.57 during the last trading session, reaching $25.13. About 462,789 shares traded. Intellia Therapeutics, Inc. (NASDAQ:NTLA) has risen 89.34% since June 12, 2017 and is uptrending. It has outperformed by 76.77% the S&P500. Some Historical NTLA News: ; 21/05/2018 – Intellia Therapeutics Presenting at JMP Conference Jun 20; 17/05/2018 – INTELLIA THERAPEUTICS ANNOUNCES WT1 AS ITS FIRST CELL THERAPY TARGET, FOLLOWING PRESENTATION OF EARLY DATA AT THE AMERICAN SOCIETY OF GENE AND CELL THERAPY 21ST ANNUAL MEETING; 14/03/2018 Intellia Therapeutics 4Q Loss/Shr 61c; 17/05/2018 – lntellia Therapeutics Announces WT1 as Its First Cell Therapy Target, Following Presentation of Early Data at the American Society of Gene and Cell Therapy 21st Annual Meeting; 17/05/2018 – Intellia Therapeutics Announces WT1 as Its First Cell Therapy Target, Following Presentation of Early Data at the American Soci; 21/04/2018 – DJ Intellia Therapeutics Inc, Inst Holders, 1Q 2018 (NTLA); 01/05/2018 – Intellia Therapeutics 1Q Loss/Shr 51c; 23/04/2018 – lntellia Therapeutics Announces In Vivo and Ex Vivo Data Presentations at the American Society of Gene and Cell Therapy 21st Annual Meeting; 10/04/2018 – Chevy Chase Trust Holdings Buys 1.4% of Intellia Therapeutics; 14/03/2018 – INTELLIA THERAPEUTICS – HAD $341 MLN IN CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2017The move comes after 7 months positive chart setup for the $1.08 billion company. It was reported on Jun, 12 by Barchart.com. We have $27.14 PT which if reached, will make NASDAQ:NTLA worth $86.64M more.

Actua Corporation operates as a multi-vertical cloud technology firm that creates value for clients and provides transformative efficiency to vertical markets worldwide. The company has market cap of $29.84 million. The firm operates through two divisions, Vertical Cloud and Vertical Cloud . It has a 0.18 P/E ratio. It provides Bolt, a cloud platform that allows large insurance carrier-agencies, independent insurance agents, and other insurance organizations with access to a range of commercial and personal property, and casualty insurance products.

More news for Actua Corporation (NASDAQ:ACTA) were recently published by: Equitiesfocus.com, which released: “Actua (NASDAQ:ACTA) Earning Somewhat Favorable News Coverage, Study Shows” on June 08, 2018. Equitiesfocus.com‘s article titled: “Actua (ACTA) Given Daily Media Impact Score of 0.22” and published on June 01, 2018 is yet another important article.

Among 4 analysts covering Intellia Therapeutics (NASDAQ:NTLA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intellia Therapeutics had 5 analyst reports since May 31, 2016 according to SRatingsIntel. The firm earned “Buy” rating on Friday, August 5 by Jefferies. The rating was initiated by Wedbush on Tuesday, May 31 with “Outperform”. The firm has “Outperform” rating given on Tuesday, May 31 by Credit Suisse. The rating was upgraded by Leerink Swann on Friday, August 5 to “Outperform”. The rating was initiated by Jefferies on Tuesday, May 31 with “Hold”.

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company has market cap of $1.08 billion. The firm develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. It currently has negative earnings. The Company’s ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells.

Analysts await Intellia Therapeutics, Inc. (NASDAQ:NTLA) to report earnings on August, 7. They expect $-0.57 earnings per share, down 26.67% or $0.12 from last year’s $-0.45 per share. After $-0.51 actual earnings per share reported by Intellia Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 11.76% negative EPS growth.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: